Dear Ms. Lynch:

Please refer to your new drug application (NDA) dated September 21, 2004, received September 22, 2004, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Rozerem (ramelteon) Tablets, 8 mg.

We acknowledge receipt of your submissions dated November 16, 2004, and January 14 and 20, February 4, 15, and 22, March 7, 17, and 23, April 4 and 21, May 12, June 1, 2, 15, 22, 24, 28, and 30, and July 8, 18, and 22, 2005.

This new drug application provides for the use of Rozerem (ramelteon) Tablets for the treatment of insomnia characterized by difficulty with sleep onset.

We have completed our review of this application, as amended, and it is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert, and carton and immediate container labels, submitted July 22, 2005). Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit an electronic version of the FPL according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA and Providing Regulatory Submissions in Electronic Format-Content of Labeling. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission “FPL for approved NDA 21-782.” Approval of this submission by FDA is not required before the labeling is used.
All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are deferring submission of your pediatric studies for ages 0 through 16 years until July 22, 2012.

Your deferred pediatric studies required under section 2 of the Pediatric Research Equity Act (PREA) are considered a required postmarketing study commitment. The status of these postmarketing studies shall be reported annually according to 21 CFR 314.81. This commitment is listed below.

1. Deferred pediatric study under PREA for the treatment of insomnia characterized by difficulty with sleep onset in pediatric patients ages 0 through 16.

   Final Report Submission: July 22, 2012

Submit final study reports to this NDA. For administrative purposes, all submissions related to this pediatric postmarketing study commitment should be clearly designated “Required Pediatric Study Commitment.”

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Anesthesia, Analgesia, and Rheumatology Products and two copies of both the promotional materials and the package insert directly to:

   Division of Drug Marketing, Advertising, and Communications, HFD-42
   Food and Drug Administration
   5600 Fishers Lane
   Rockville, MD 20857

The expiration dating period for Rozerem (ramelteon) Tablets packaged in bottles of 30, 100, and 500 tablets is 24 months. As discussed during the teleconference on July 20, 2005, you may submit a “Supplement-Changes Being Effected” (CBE-0) for extension of expiration dating following accrual of additional real-time data and statistical analysis as recommended in ICH Q1E.

Please submit one market package of the drug product when it is available.

We have not completed validation of the regulatory methods. However, we expect your continued cooperation to resolve any problems that may be identified.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at www.fda.gov/medwatch/report/mmp.htm.
If you have any questions, call Sara Stradley, Regulatory Project Manager, at (301) 827-7430.

Sincerely,

{See appended electronic signature page}

Robert J. Meyer, MD
Director
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosures:
Package Insert
Carton Labels
Immediate Container Labels
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

---------------------
Robert Meyer
7/22/05 04:31:23 PM